Changchun Deng

Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.

Michael R Savona, Michael S Weiss, I. Flinn, 2018, The Lancet. Oncology.